Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.32 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.43 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL933391 | 0.98 | MAPT (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Hydrochloric Acid SCHEMBL2355625 | 0.98 | MAPT (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| SCHEMBL8010 | 0.97 | BBOX1 (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| SCHEMBL14742785 | 0.97 | BBOX1 (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Bromide SCHEMBL8416789 | 0.95 | BBOX1 (0.39) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Water SCHEMBL17373732 | 0.95 | BBOX1 (0.39) | MAPTBBOX1SLC22A16SMN1; SMN2GALR3 | |
| Hydroxyamine SCHEMBL8584616 | 0.93 | BBOX1 (0.43) | MAPTBBOX1SLC22A16LMNATSHR | |
| Phosphoric Acid SCHEMBL9095324 | 0.91 | BBOX1 (0.41) | MAPTBBOX1SLC22A16SMN1; SMN2TSHR | |
| Glycerin SCHEMBL691939 | 0.87 | SLC22A16 (0.42) | MAPTBBOX1SLC22A16SMN1; SMN2LMNA | |
| Hexane SCHEMBL3645235 | 0.87 | FDPS (0.47) | BBOX1FDPSLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136841-A1 | BLENDED FURNISH WITH IMPROVED PERFORMANCE AND METHODS OF MAKING AND USING THE SAME | ARCLIN USA LLC (US) | 2025-05-01 | — | — | US | claimed |
| US-6017721-A | CONTACTING SERUM FROM A PATIENT WITH LIGANDS THAT BIND WARM AUTOANTIBODIES BUT DO NOT BIND ALLOANTIBODIES, SEPARATING NON-BOUND SERUM COMPONENTS FROM BOUND WARM AUTOANTIBODIES, USING WARM AUTOANTIBODY-DEPLETED SERUM IN ANTIGLOBIN TESTING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-01-25 | — | — | US | claimed |
| WO-2025262036-A1 | METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION | RNASSIST LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| CN-119923068-A | Perovskite battery with self-assembled monolayer and preparation method | 中核光电科技(上海)有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250136841-A1 | BLENDED FURNISH WITH IMPROVED PERFORMANCE AND METHODS OF MAKING AND USING THE SAME | ARCLIN USA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250011738-A1 | HEAT TOLERANT ALKALINE PHOSPHATASE | BIOMEDIT, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-3827241-B1 | DISSOCIATION OF BIOLOGICAL SAMPLES | GOLDSBOROUGH ANDREW SIMON (FR) | 2024-03-13 | — | — | EP | disclosed |
| US-20240027309-A1 | SIMPLE FIXATION AND STABILISATION | RNASSIST LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20230420260-A1 | POLISHING LIQUID COMPOSITION FOR SILICON OXIDE FILM | KAO CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| US-20230220313-A1 | COMPOSITION AND METHOD FOR INACTIVATING A VIRUS | RNASSIST LTD. (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4133062-A1 | COMPOSITION AND METHOD FOR INACTIVATING A VIRUS | Rnassist Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| EP-1141153-A1 | CROSSLINKING AGENT FOR CARBOXYL-CONTAINING POLYMERS IN HEAT-CURABLE SYSTEMS | Vantico AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| US-6100349-A | Thermosetting powder coating composition | AKZO NOBEL N.V. (NL) | 2000-08-08 | — | — | US | disclosed |
| WO-2000029497-A1 | CROSSLINKING AGENT FOR CARBOXYL-CONTAINING POLYMERS IN HEAT-CURABLE SYSTEMS | VANTICO AG (CH) | 2000-05-25 | — | — | WO | disclosed |
| EP-0871682-B1 | THERMOSETTING POWDER COATING COMPOSITION | AKZO NOBEL NV (NL) | 2000-02-02 | — | — | EP | disclosed |
| US-6017721-A | CONTACTING SERUM FROM A PATIENT WITH LIGANDS THAT BIND WARM AUTOANTIBODIES BUT DO NOT BIND ALLOANTIBODIES, SEPARATING NON-BOUND SERUM COMPONENTS FROM BOUND WARM AUTOANTIBODIES, USING WARM AUTOANTIBODY-DEPLETED SERUM IN ANTIGLOBIN TESTING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-01-25 | — | — | US | disclosed |
| US-5962588-A | CONTAINING BLOCKED HYDROXYL GROUPS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1999-10-05 | — | — | US | disclosed |
| EP-0871682-A1 | THERMOSETTING POWDER COATING COMPOSITION | Akzo Nobel N.V. (NL) | 1998-10-21 | — | — | EP | disclosed |
| CN-1182368-A | Immanomodulating compositions from bile for treatment of immune system disorders | IMUTEC CORP (CA) | 1998-05-20 | — | — | CN | disclosed |
| WO-1997024408-A1 | THERMOSETTING POWDER COATING COMPOSITION | AKZO NOBEL N.V. (NL) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240027309-A1 | SIMPLE FIXATION AND STABILISATION | EWSR1, FOSB, PAXBP1 | CHRM2 4753/4885CHRM1 4831/4885CHRM3 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.